ABPRO BIO CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 511 KRW | -1.54% |
|
+4.07% | -6.24% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 75,465 | 142,117 | 461,443 | 244,023 | 115,496 | 155,155 |
| Enterprise Value (EV) 1 | 114,038 | 171,895 | 441,953 | 211,443 | 104,603 | 147,080 |
| P/E ratio | -5.63 x | -2.94 x | -6.28 x | -22.3 x | -13.9 x | -5.89 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 1.28 x | 4.45 x | 9.36 x | 7.41 x | 5.22 x | 6.11 x |
| EV / Revenue | 1.94 x | 5.38 x | 8.97 x | 6.42 x | 4.73 x | 5.8 x |
| EV / EBITDA | 7,775 x | -6.69 x | -556 x | -78.1 x | -10.7 x | -17.7 x |
| EV / FCF | -47.8 x | -7.42 x | 33.4 x | -16.6 x | -15.6 x | -21.9 x |
| FCF Yield | -2.09% | -13.5% | 2.99% | -6.02% | -6.42% | -4.56% |
| Price to Book | 0.72 x | 1.1 x | 3.32 x | 1.83 x | 0.82 x | 1.27 x |
| Nbr of stocks (in thousands) | 96,379 | 176,762 | 251,468 | 252,874 | 273,688 | 284,688 |
| Reference price 2 | 783.0 | 804.0 | 1,835 | 965.0 | 422.0 | 545.0 |
| Announcement Date | 3/19/19 | 3/13/20 | 3/22/21 | 3/31/22 | 3/23/23 | 3/21/24 |
1KRW in Million2KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 58,911 | 31,930 | 49,282 | 32,914 | 22,112 | 25,375 |
| EBITDA 1 | 14.67 | -25,686 | -794.6 | -2,708 | -9,791 | -8,305 |
| EBIT 1 | -5,985 | -30,149 | -8,043 | -5,333 | -11,193 | -10,175 |
| Operating Margin | -10.16% | -94.42% | -16.32% | -16.2% | -50.62% | -40.1% |
| Earnings before Tax (EBT) 1 | -13,165 | -34,923 | -59,176 | -9,675 | -8,145 | -25,658 |
| Net income 1 | -11,058 | -35,694 | -58,972 | -10,030 | -8,145 | -25,742 |
| Net margin | -18.77% | -111.79% | -119.66% | -30.47% | -36.83% | -101.44% |
| EPS 2 | -139.0 | -273.4 | -292.1 | -43.31 | -30.36 | -92.51 |
| Free Cash Flow 1 | -2,387 | -23,160 | 13,227 | -12,719 | -6,719 | -6,703 |
| FCF margin | -4.05% | -72.53% | 26.84% | -38.64% | -30.38% | -26.41% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/19/19 | 3/13/20 | 3/22/21 | 3/31/22 | 3/23/23 | 3/21/24 |
1KRW in Million2KRW
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 38,573 | 29,778 | - | - | - | - |
| Net Cash position 1 | - | - | 19,491 | 32,581 | 10,893 | 8,075 |
| Leverage (Debt/EBITDA) | 2,630 x | -1.159 x | - | - | - | - |
| Free Cash Flow 1 | -2,387 | -23,160 | 13,227 | -12,719 | -6,719 | -6,703 |
| ROE (net income / shareholders' equity) | -10.6% | -26.2% | -47.9% | -7.06% | -5.87% | -19.6% |
| ROA (Net income/ Total Assets) | -2.15% | -10.3% | -2.73% | -2% | -4.31% | -4.26% |
| Assets 1 | 514,933 | 346,100 | 2,163,952 | 502,446 | 188,914 | 604,657 |
| Book Value Per Share 2 | 1,085 | 731.0 | 553.0 | 529.0 | 512.0 | 430.0 |
| Cash Flow per Share 2 | 71.40 | 84.60 | 107.0 | 207.0 | 61.90 | 66.20 |
| Capex 1 | 1,305 | 2,786 | 271 | 542 | 132 | 1,148 |
| Capex / Sales | 2.21% | 8.73% | 0.55% | 1.65% | 0.6% | 4.53% |
| Announcement Date | 3/19/19 | 3/13/20 | 3/22/21 | 3/31/22 | 3/23/23 | 3/21/24 |
1KRW in Million2KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -6.24% | 106M | |
| +54.30% | 3.74B | |
| +8.22% | 2.04B | |
| +0.43% | 1.99B | |
| -6.79% | 1.91B | |
| -5.37% | 1.38B | |
| +15.70% | 1.36B | |
| -16.05% | 1.38B | |
| -28.65% | 1.3B | |
| -17.02% | 1.24B |
- Stock Market
- Equities
- A195990 Stock
- Financials Abpro Bio Co., Ltd.
